The United States Food and Drug Administration recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Pharmacokinetic data confirm equivalent drug exposure in this population as that found in adults during clinical trials. The efficacy and safety of these drugs has been shown in clinical trials.
|Original language||English (US)|
|Number of pages||5|
|Journal||Drugs of Today|
|State||Published - Aug 1 2017|
- Hepatitis C
ASJC Scopus subject areas
- Pharmacology (medical)